ClinicalTrials.gg
RecruitingNCT04300062REBIMMUNEUpdated Sep 3, 2025

Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer

An interventional study of Rebiopsy in Lung Cancer, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Aug 2020; still recruiting 6 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 9 under way, none of them phase 3. Lung Neoplasms · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
10th of 12
50 · median 235
Started
2020
with 1 other
No phase
8 of 19
5 open now
Registered
11th of 19
by date

Among the 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2020, is one of 8 with no phase, and was the 11th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

9 of the 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The objective of the study aims to collect tumor tissue at the moment of progression under Immune checkpoint inhibitors (ICI) in biological resources center in Ambroise Paré hospital, in order to insure later study on molecular mechanism involving the progression of NSCLC and SCLC under ICI.

The further analysis of research will be performed in the EA 4340 unity, Biomarkers and Clinical Trials in cancerology and onco-hematology, UVSQ, University of Paris-Saclay.

Read the detailed description

The study will consist of creation a tumor tissue bank, all sampling will be stored in the biological resources center of Ambroise Paré hospital.

03

Conditions studied

  • Lung Cancer

Keywords

  • lung cancer
  • rebiopsy
  • immunotherapy
  • progression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed NSCLC or SCLC;
  • Patient treated priorly by ICI and progressed under ICI;
  • Have provided written for the study;
  • Be >/= 18 years of age on day of signing informed consent.

Exclusion criteria

Exclusion Criteria:

  • Patient under guardianship or curatorship;
  • Unable to provide written for the study;
  • Technical impossibility to carry out tissular rebiopsy under local anesthesia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Rebiopsy

    Procedure: Rebiopsy

Interventions

  • ProcedureRebiopsy

    Biopsy will be carry out with flexible bronchoscopy as usual practice under local anesthesia: under endobronchial ultrasound, punction under CT scan or ultrasonography, percutaneous pleural puncturing.

06

What researchers measure

Primary outcomes

  1. Incidence of specific histomolecular resistance

    Banking of tumor samples at progression with immune checkpoint inhibitor (ICI) in lung cancer, to evaluate the incidence of specific histomolecular resistance mechanisms to ICI by immunohistochemistry and molecular testing.

    Time frame: At the end of study, up to 2 years

07

Study locations

1 of 1 sites recruiting
  • Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP
    Boulogne-Billancourt, 92100, France
    Recruiting
08

References and documents

Publications

  • Giroux Leprieur E, Dumenil C, Julie C, Giraud V, Dumoulin J, Labrune S, Chinet T. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. Eur J Cancer. 2017 Jun;78:16-23. doi: 10.1016/j.ejca.2016.12.041. Epub 2017 Apr 11. PubMed 28407528 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Aug 2027, 84 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 84 months is above that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2020
First posted
Mar 9, 2020
StartActual
Aug 18, 2020
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04300062
Responsible party
Sponsor
First posted
Mar 9, 2020
Start date
Aug 18, 2020
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 3, 2025

Study contacts

Etienne Giroux Leprieur, MD, PhD
Contact
etienne.giroux-leprieur@aphp.fr
+33 1 49 09 58 02
Etienne Giroux Leprieur, MD, PhD
principal investigator · Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion